Triplet Therapeutics

📍 Cambridge, United States🗓 Founded 2019👥 34 employees💰 Last funded Jun 2020
Biotechnology🌐 triplettx.com
Website LinkedIn
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Triplet Therapeutics?
Triplet Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Triplet Therapeutics last raise funding?
The most recent investment in Triplet Therapeutics recorded on gritt.io was in June 2020.
When was Triplet Therapeutics founded?
Triplet Therapeutics was founded in 2019.
What industry is Triplet Therapeutics in?
Triplet Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Triplet Therapeutics based?
Triplet Therapeutics is headquartered in Cambridge, United States.